slide1
Download
Skip this Video
Download Presentation
June 2007

Loading in 2 Seconds...

play fullscreen
1 / 33

June 2007 - PowerPoint PPT Presentation


  • 125 Views
  • Uploaded on

CHANGES TO THE GENE TECHNOLOGY ACT, REGULATIONS & GUIDELINES Information for Accredited Organisations, IBCs & Researchers. June 2007. Purpose of this session.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' June 2007' - eze


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

CHANGES TO THE GENE TECHNOLOGY ACT, REGULATIONS & GUIDELINESInformation forAccredited Organisations, IBCs & Researchers

June 2007

purpose of this session
Purpose of this session

To inform organisations, IBCs & researchers using gene technology of recent and imminent changes to Gene Technology regulation, and their implications

slide3

Overview

  • Background to changes:
    • Why ? How ? What ? When ?
  • Changes to:
    • Gene Technology Act
    • Gene Technology Regulations
    • Guidelines
  • Implementation & implications
slide5

WHY have changes been made ?

(i) REGULATOR’sREVIEW of the Gene Technology Regulations in response to stakeholders & operational experience – amendments commenced 31 March 2007

(ii) INDEPENDENT REVIEWof the operation of the Gene Technology Act – amendments to commence 1 July 2007

slide6

i. Regulator’s Review - Overview

  • Initiated in response to stakeholder & OGTR experience
  • Within existing policy setting
    • Technical changes only
  • Extensive consultation & drafting
    • Included GTTAC, risk assessments
  • Approved by States/Territories
slide7

i. Regulator’s Review – 2006 Regulations

  • Expanded list of host-vector systems
  • Regulations clarified (e.g. complementation, viral vectors, oncogenes, pathogenic)
  • More flexible information requirements
  • Appropriate regulation of organisms with history of safe usage
  • Commenced 31 March 2007
slide8

ii. Independent Review - Purpose

  • Scope, object & operation of Act
  • Regulatory burden
  • Interface with other systems
  • Review inter-governmental agreement
  • State/Territory/Commonwealth response October 2006
slide9

ii. Independent Review – Act changes

  • Variation application – 90 day decision
  • Emergency provision – rapid approval to address threat, issued by Minister, limited period
  • Inadvertent dealings – ‘unintended possession’ temporary licence for disposal
  • Advisory committees – combine GTEC with GTCCC (December 2007)
  • Direction Powers – clarify Regulator’s ability to direct
slide10

ii. Independent Review – Act changes

Dealings Involving Intentional Release (DIRs)

  • New ‘limited & controlled’ category (e.g. field trial)
    • for ‘experimental’ purpose
    • containment proposed by applicant
    • 1 round of consultation
    • 150 days (or 170 days if ‘significant risk’)
  • Intentional release (e.g. commercial) - 255 days
  • 1 July 2007 commencement
slide11

ii. Independent Review - 2007 Regulations

  • No mandated containment of exempt dealings
  • New class of (PC1) NLRDs
  • Annual NLRD reporting only
  • Subject to passage of legislation
  • 1 July 2007 commencement
slide12

ii. Independent Review – Other

  • No reporting of exempt dealings
  • Harmonisation of guidelines
    • PC2, PC4 Certification Guidelines
    • Transport Guidelines
    • Accreditation Guidelines
  • Co-operation with other regulators
  • 1 July 2007 commencement
slide14

Non - GMOs

i. Regulator’s Review- from 31 March 2007

  • Schedule 1 (non-GMOs) now includes:
    • Naked plasmid DNA (clarification)
    • Introduction of naked recombinant nucleic acid into somatic cells (previously Exempt)
  • New Schedule 1Alists techniques that are not gene technology
shifting regulatory oversight
Shifting Regulatory Oversight

Other GM animals & plants

In vitro human VV + oncogene

Tg mice & rats

Non-exempt H/V + oncogene etc

Non-exempt H/V + e.g. GFP

Large scale +

exempt H/V

GM viruses, toxins etc

Exempt H/V + e.g. GFP

Knockout mice

21 June 2001

EXEMPT

NLRD

DNIR

31 March 2007

EXEMPT

NLRD

DNIR

1 July 2007

EXEMPT

PC2 NLRD

DNIR

PC1 NLRD

slide16

31 March 2007

1 July 2007

Containment

  • Conducted according to Regulators guidelines
  • No intentional release
  • No specified containment
  • (still) No intentional release

Dealings

  • Increased exempt host/vector list
  • More dealings exempt eg GM mice/rats, C. elegans

Removal of some viral vectors & GM mice/rats from exempt

Forms

No Change (no forms)

No Change (no forms)

Oversight

No Change (annual Reporting)

Remove all reporting requirements

Exempt Dealings

slide17

NLRDs

i. Regulators Review- from 31 March 2007

  • Reclassification of dealings
    • Increase from 5 to 12 types of NLRD
  • Changes to dealings that involve:
    • Viral vectors able to transduce human cells (clarified as NLRD)
    • Complementation of knockouts (now NLRD)
    • Large-scale low risk (now NLRD)
slide18

NLRDs

ii. Independent Review –from 1 July 2007

  • New PC1 NLRD category:
    • GM mice & rats
    • Oncogenic modification in exempt host/vector
    • Viral vectors able to transduce human cells
  • PC2 NLRD:
    • Same as current dealings & requirements
slide19

Forms

  • Removal of Information requirements from Regs
  • New short forms

New internal IBC form

Oversight

Can start after IBC notifies OGTR

Can start after IBC assessment (only annual reporting to OGTR)

NLRDs

slide20

Forms

Oversight

  • New surrender forms
  • Info requirements removed from Regs

No change (DNIR application vetted by IBC then sent to OGTR for evaluation)

No change

No change

Dealings

  • Downgrading of licences to NLRDs e.g.V V’s in tissue culture, large scale low risk
  • Older lentiviral vectors, impairment of disease treatment now DNIR

No change

DNIRs

slide21

Viral Vectors

  • Recognition of :
    • In vitrovs In vivo
    • Ability to enter human cells
    • Context of inserted gene
    • Replication defective vs replication competent
  • Table of dealings on OGTR IBC web page
slide22

Viral Vectors

VECTOR

HOST

GENE

CLASSIFICATION

2001

31 MARCH

1 JULY

Non-retroviral vector which cannot transduce human cells eg. FAV

In vitro

Marker

Exempt

Exempt

Exempt

Higher risk gene e.g. oncogene

NLRD (e)

Exempt

PC1 NLRD (b)

In vivo

Marker

NLRD (c)

NLRD (c/d)

PC2 NLRD (c/d)

Higher risk gene

DNIR

DNIR

DNIR

Non-retroviral vector which can transduce human cells

eg. Ad5

In vitro

Marker

Exempt

Exempt

PC1 NLRD (c)

Higher risk gene e.g. oncogene

NLRD (e)

NLRD (e)

PC2 NLRD (i)

In vivo

Marker

NLRD (c)

NLRD (c/d)

PC2 NLRD (c/d)

Higher risk gene

DNIR

DNIR

DNIR

slide24

Exempt and PC1 Guidelines

  • Exempt dealings guidelines
    • Required minimum for exempt dealings until 1 July
    • ‘guidance’ only after 1 July
  • Certified PC1 guidelines
    • Required for PC1 NLRD after 1 July
slide25

PC2 & PC4 Guidelines

  • PC2 lab/animal/plant Certification guidelines:
    • Requirements before Certification
    • Conditions of certification ongoing
    • Behavioural requirements (for GMO work only)
    • Outcome-focus & Regulator’s power to exclude persons
  • PC4 Certification Guidelines - more detailed
  • One application form for all facility types
  • Commence 1 July 2007
slide26

Other Guidelines

  • Transport Guidelines
    • Conditions linked to containment level
    • Outcome focus e.g. decontaminate outside of container
    • Explanatory notes
  • Accreditation Guidelines
    • No ‘exempt’ dealing reporting requirement
    • Must have IBC (own/other) in place
    • New instruments to be issued
  • Commence1 July 2007
slide28

Transitional Arrangements

  • IBCs apply to OGTR for DNIR  NLRD
    • IBCs & project supervisors notified
  • NLRD  DNIR
    • if already started must have new licence by 31 March 2008
    • if new need licence before starting
slide29

Transitional Arrangements cont…

  • NLRD  Exempt
    • IBCs & researchers determine category
  • Exempt  PC1 NLRD
    • No new NLRD required if approved before 31 March
    • If started between 31 March – 30 June must have IBC approval
    • PC1 certification required by 1 July 2007
slide30

Impact on IBCs

  • More NLRDs & Exempt (rather than DNIRs)
  • IBC oversight of Exempt & NLRD dealings (exempt dealings not reported, annual reporting only for NLRDs) (from 1 July 2007)
  • No specified containment for Exempt dealings (from 1 July 2007)
  • Fewer PC2 animal facilities required (PC1 for GM rats & mice from 1 July 2007)
future changes
FUTURE CHANGES
  • Targeted amendments to Regulations
  • Submit a case (with scientific evidence) through IBC to Gene Technology Regulator
slide32

Summary

  • Exempt truly exempt - from1 July
  • New PC1 NLRD - from1 July
  • Overall less administration for IBCs
  • Transitional arrangements
  • Guidance on OGTR website - IBC page

www.ogtr.gov.au/ibc/index.htm

ad